Skip to main content

Table 4 Relationship between time-to-remission and sustained remission

From: Time to achieve remission determines time to be in remission

 

All patients (n = 753)

1985-1990

(n = 147)

1991-1995

(n = 158)

1996-2000

(n = 219)

2001-2005

(n = 229)

DAS remission

     

Achieving remission (n [%]) 1

398 [53%]

77 [52%]

68 [43%]

124 [57%]

129 [56%]

Time-to-remission

(median [IQR], months)

33

[11-36]

35

[14-36]

36

[12-36]

28

[9-36]

26

[9-36]

Sustained remission (n [%]) 2

142 [36%]

22 [29%]

25 [37%]

46 [37%]

49 [38%]

Time in sustained remission

(median [IQR], months])

19

[10-28]

9

[6-22]

22

[14-29]

18

[10-26]

22

[13-29]

Relationship between time to

achieve and sustained remission

(OR [95%CI]) 3

1.11

[1.10-1.12]

1.09

[1.07-1.11]

1.15

[1.12-1.17]

1.09

[1.08-1.11]

1.13

[1.11-1.15]

mACR remission

     

Achieving remission (n [%]) 4

226 [30%]

48 [33%]

45 [29%]

62 [28%]

71 [31%]

Time-to-remission

(median [IQR], months)

13

[8-24]

15

[10-28]

13

[7-24]

15

[9-23]

10

[7-19]

Sustained remission (n [%]) 5

58 [26%]

8 [17%]

18 [33%]

13 [21%]

19 [27%]

Time in sustained remission

(median [IQR], months])

10

[6-16]

7

[6-8]

11

[7-16]

7

[6-16]

13

[7-24]

Relationship between time to

achieve and sustained remission

(OR [95%CI]) 3

1.15

[1.14-1.16]

1.13

[1.09-1.16]

1.12

[1.07-1.18]

1.08

[0.96-1.22]

1.12

[0.93-1.16]

  1. 1 Number of patients achieving at least one period of remission (disease activity score, DAS<1.6) during 3 years follow-up. 2 Number of patients who had sustained DAS remission (6 months or more) during 3 years follow-up. 3 Odds ratios (ORs) of remission during 3 years follow-up analyzed by longitudinal binary regression with remission status over time as dependent variable, time-to-remission (months) and DAS value of the previous visit as main covariates. 4 Number of patients achieving at least one period of remission (modified American College of Rheumatology, mACR) during 3 years follow-up. Fulfillment of the mACR remission criteria was based on 4 of the following 5 criteria to be met: 1) morning stiffness ≤ 15 minutes, 2) VAS pain ≤ 10 mm, 3) no tender joints (out of 53 joints), 4) no swollen joints (out of 44 joints), and 5) ESR < 30 mm/h (female) or < 20 mm/h (male). 5 Number of patients who had sustained mACR remission (6 months or more) during 3 years follow-up. IQR = interquartile range, P25-P75; CI = confidence interval.